MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists
• •Brain metastases allowed provided both of the following criteria are met:
• •* Received treatment for the brain metastases
• •* Stable for ≥ 6 months without steroids or antiseizure medications
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •ECOG 0-2 OR
• •Karnofsky 50-100%
• •Life expectancy:
• •More than 3 months
• •Hematopoietic:
• •WBC at least 3,000/mm\^3
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hepatic:
• •Bilirubin no greater than 1.5 times upper limit of normal (ULN) (≤ 3 mg/dL for patients with Gilbert's syndrome)
• •AST/ALT no greater than 2.5 times ULN
• •Albumin at least 75% of lower limit of normal
• •Renal:
• •Creatinine normal OR
• •Creatinine clearance at least 60 mL/min
• •Cardiovascular:
• •Cardiac ejection fraction normal by MUGA
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •No cardiac arrhythmia
• •Other:
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •Adequate oral intake
• •No weight loss of more than 10% of actual body weight within the past 2 months
• •No history of allergic reaction to compounds of similar chemical or biological composition to study drug
• •No other uncontrolled illness
• •No ongoing or active infection
• •No seizure disorder
• •No psychiatric illness or social situation that would preclude study compliance
• •No acute or chronic gastrointestinal conditions (e.g., peptic ulcer or colitis) within the past 2 months that would interfere with drug tolerance or absorption
• •Willing and able to self-administer and document doses of MS-275
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 4 weeks since prior anticancer vaccine therapy and recovered
• •No concurrent immunotherapy
• •Chemotherapy:
• •At least 4 weeks since prior anticancer chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• •At least 8 weeks since prior UCN-01 and recovered
• •No concurrent chemotherapy
• •Endocrine therapy:
• •At least 4 weeks since prior anticancer hormonal therapy (except gonadotropin-releasing hormone \[GnRH\] agonists) and recovered
• •Concurrent corticosteroids for physiological replacement, as antiemetic therapy, or for an ongoing condition allowed
• •* Must be on a stable dose during the past 4 weeks
• •No concurrent anticancer hormonal therapy except GnRH agonists for noncastrated patients with prostate cancer
• •Radiotherapy:
• •At least 4 weeks since prior anticancer radiotherapy and recovered
• •No concurrent radiotherapy
• •* Concurrent localized radiotherapy to a single lesion allowed if the patient achieves at least a partial response
• •Surgery:
• •At least 3 weeks since prior major surgery
• •Other:
• •No other concurrent investigational or commercial antineoplastic therapies